The effect of intravenous immunoglobulins on the outcomes of patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials

References

• Organization WH. https://covid19.who.int/ Accessed on 2021 Nov 30).
   Google Scholar
• Lai CC, Liu YH, Wang CY, et al. Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): facts and myths. J Microbiol Immunol Infect. 2020;53(3):404–412.
   PubMedGoogle Scholar
• Berlin DA, Gulick RM, Martinez FJ. Severe Covid-19. N Engl J Med. 2020;383(25):2451–2460.
   PubMed Web of Science ®Google Scholar
• Hu Y, Sun J, Dai Z, et al. Prevalence and severity of Corona virus disease 2019 (COVID-19): a systematic review and meta-analysis. J Clin Virol. 2020;127:104371.
   PubMed Web of Science ®Google Scholar
• Dessie ZG, Zewotir T. Mortality-related risk factors of COVID-19: a systematic review and meta-analysis of 42 studies and 423,117 patients. BMC Infect Dis. 2021;21(1):855.
   PubMed Web of Science ®Google Scholar
• Shi Q, Wang Z, Liu J, et al. Risk factors for poor prognosis in children and adolescents with COVID-19: a systematic review and meta-analysis. EClinicalMedicine. 2021;41:101155.
   PubMedGoogle Scholar
• Tan E, Song J, Deane AM, et al. Global impact of coronavirus disease 2019 infection requiring admission to the ICU: a systematic review and meta-analysis. Chest. 2021;159(2):524–536.
   PubMed Web of Science ®Google Scholar
• Lin WT, Hung SH, Lai CC, et al. The impact of neutralizing monoclonal antibodies on the outcomes of COVID-19 outpatients: a systematic review and meta-analysis of randomized controlled trials. J Med Virol. 2022;94(5):2222–2229.
   PubMed Web of Science ®Google Scholar
• Pearce L, Davidson SM, Yellon DM. The cytokine storm of COVID-19: a spotlight on prevention and protection. Expert Opin Ther Targets. 2020;24(8):723–730.
   PubMed Web of Science ®Google Scholar
• Savitt AG, Manimala S, White T, et al. SARS-CoV-2 Exacerbates COVID-19 pathology through activation of the complement and kinin systems. Front Immunol. 2021;12:767347.
   PubMed Web of Science ®Google Scholar
• Jarlhelt I, Nielsen SK, Jahn CXH, et al. SARS-CoV-2 antibodies mediate complement and cellular driven inflammation. Front Immunol. 2021;12:767981.
   PubMed Web of Science ®Google Scholar
• Shankar-Hari M, Vale CL, Godolphin PJ, et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis. Jama. 2021;326(6):499–518.
   PubMed Web of Science ®Google Scholar
• Sterne JAC, Murthy S, Diaz JV, et al. Association between administration of systemic corticosteroids and mortality among critically Ill patients with COVID-19: a meta-analysis. Jama. 2020;324(13):1330–1341.
   PubMed Web of Science ®Google Scholar
• Tjon AS, van Gent R, Geijtenbeek TB, et al. Differences in anti-inflammatory actions of intravenous immunoglobulin between mice and men: more than meets the eye. Front Immunol. 2015;6:197.
   PubMed Web of Science ®Google Scholar
• Mouthon L, Kaveri SV, Spalter SH, et al. Mechanisms of action of intravenous immune globulin in immune-mediated diseases. Clin Exp Immunol. 1996;104 Suppl 1:3–9.
   PubMed Web of Science ®Google Scholar
• Xiang HR, Cheng X, Li Y, et al. Efficacy of IVIG (intravenous immunoglobulin) for Corona virus disease 2019 (COVID-19): a meta-analysis. Int Immunopharmacol. 2021;96:107732.
   PubMed Web of Science ®Google Scholar
• Hung IFN, Kkw T, Lee CK, et al. Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection. Chest. 2013;144(2):464–473.
   PubMed Web of Science ®Google Scholar
• Mustafa S, Balkhy H, Gabere MN. Current treatment options and the role of peptides as potential therapeutic components for middle east respiratory syndrome (MERS): a review. J Infect Public Health. 2018;11(1):9–17.
   PubMed Web of Science ®Google Scholar
• Luke TC, Casadevall A, Watowich SJ, et al. Hark back: passive immunotherapy for influenza and other serious infections. Crit Care Med. 2010;38(4 Suppl):e66–73.
   PubMedGoogle Scholar
• Sakoulas G, Geriak M, Kullar R, et al. Intravenous immunoglobulin plus methylprednisolone mitigate respiratory morbidity in coronavirus disease 2019. Crit Care Explor. 2020;2(11):e0280.
   PubMedGoogle Scholar
• Raman RS, Bhagwan Barge V, Anil Kumar D, et al. A phase II safety and efficacy study on prognosis of moderate pneumonia in coronavirus disease 2019 patients with regular intravenous immunoglobulin therapy. J Infect Dis. 2021;223(9):1538–1543.
   PubMed Web of Science ®Google Scholar
• Mazeraud A, Jamme M, Mancusi RL, et al. Intravenous immunoglobulins in patients with COVID-19-associated moderate-to-severe acute respiratory distress syndrome (ICAR): multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2021;10(2):158–166.
   PubMed Web of Science ®Google Scholar
• Tabarsi P, Barati S, Jamaati H, et al. Evaluating the effects of intravenous immunoglobulin (IVIg) on the management of severe COVID-19 cases: a randomized controlled trial. Int Immunopharmacol. 2021;90:107205.
   PubMed Web of Science ®Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. Updating guidance for reporting systematic reviews: development of the PRISMA 2020 statement. J Clin Epidemiol. 2021;134:103–112.
   PubMed Web of Science ®Google Scholar
• Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane collaboration’s tool for assessing risk of bias in randomised trials. Bmj. 2011;343(Oct18 2):d5928.
   PubMedGoogle Scholar
• Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. 2005;5(1):13.
   PubMedGoogle Scholar
• Wan X, Wang W, Liu J, et al. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14:135.
   PubMed Web of Science ®Google Scholar
• Ali S, Uddin SM, Shalim E, et al. Hyperimmune anti-COVID-19 IVIG (C-IVIG) treatment in severe and critical COVID-19 patients: a phase I/II randomized control trial. EClinicalMedicine. 2021;36:100926.
   PubMedGoogle Scholar
• Gharebaghi N, Nejadrahim R, Mousavi SJ, et al. The use of intravenous immunoglobulin gamma for the treatment of severe coronavirus disease 2019: a randomized placebo-controlled double-blind clinical trial. BMC Infect Dis. 2020;20(1):786.
   PubMed Web of Science ®Google Scholar